Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$2.60 – $5.04
36% from low
Exchange
OTC Link
OS
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $12.7M | $15.2M | $73.9M | $73.9M | $19.2M | $755.0K | $41.5M | $75.9M |
| Cost of revenue | $2.7M | $11.4M | $36.3M | $36.3M | $1.8M | $737.0K | $9.2M | $20.9M |
| Gross profit | $10.0M | $3.8M | $37.7M | $37.7M | $17.4M | $18.0K | $41.5M | $55.0M |
| Gross margin | 78.5% | 25.0% | 50.9% | 50.9% | 90.8% | 2.4% | 100.0% | 72.5% |
| R&D | $76.6M | $92.0M | $87.0M | $87.0M | $97.5M | $87.6M | $90.5M | $97.3M |
| Operating income | −$105.1M | −$123.6M | −$85.4M | −$85.4M | −$89.7M | −$108.9M | −$59.6M | −$42.0M |
| EBITDA | −$90.9M | −$105.7M | −$40.6M | −$83.1M | −$76.4M | −$92.6M | −$15.2M | −$21.1M |
| Net income | −$78.7M | −$102.1M | −$81.1M | −$81.1M | −$106.1M | −$103.2M | −$36.8M | −$70.3M |
| Net margin | -618.1% | -672.1% | -109.6% | -109.6% | -553.6% | -13665.4% | -88.6% | -92.7% |
| EPS (diluted) | -1.93 | -2.41 | -1.91 | -1.81 | -2.33 | -1.77 | -0.41 | -0.70 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $59M | $-0.89 | $-1.72–$-0.24 | 1 |
| 2027 | $114M | $-0.72 | $-1.39–$-0.20 | 1 |
| 2028 | $71M | $-1.27 | $-2.45–$-0.35 | 1 |
| 2029 | $78M | $-1.42 | $-2.74–$-0.39 | 1 |
Forward consensus · source: Financial Modeling Prep
CELLECTIS ROMAINVILLE ORD
No one on the platform currently holds CMVLF.
No tracked institution reports a position in CMVLF as of their last filing.
No one on the platform has traded CMVLF yet.
| $194M |
| — |
| HNSBFHansa Biopharma AB | $2.90 | +0.00% | $246M | — |
| NWBONorthwest Biotherapeutics, Inc. | $0.19 | +0.00% | $312M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 6.6× sales vs its 5.9× historical median P/S.
Fair value ≈ $3.10 · price $3.47 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.